Company
Arix Bioscience PLC
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 1 of 2
Arix Bioscience updates on clinical progress of four portfolio companies
Imara, Harpoon, Autolus and LogicBio have all released news recently
Arix Bioscience concludes strategic review, reshuffles board
The biotech-focused venture capital firm said it has completed stakeholder engagement and “now has a clear understanding of shareholder views”, which it said will enable it to implement its strategy more effectively
Arix Bioscience looks to boost the cutting edge of biotech
Arix invests in disruptive growth companies with the potential to significantly increase in worth as they progress through clinical trials and conduct financing rounds at higher valuations
Arix Bioscience's portfolio firm Amplyx snapped up by Pfizer
Amplyx, which develops therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, will be acquired by Pfizer following an initial investment from the pharma giant in 2019
Arix Bioscience investee LogicBio signs strategic collaboration with CANBridge Pharma
SUNRISE is initially enrolling pediatric patients aged from 3 -12 years old, added the statement.
Arix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy development
The company said Artois will receive an upfront payment of US$20mln as part of the collaboration and will also be eligible to receive up to US$1.3bn in milestone payments as well as any sales royalties
Arix Bioscience leads US$152mln funding round for Pyxis Oncology
Arix will have a 5.6% ownership stake following the funding round
Arix Bioscience appoints biopharma veteran as venture partner
Dittmar has over 20 years of experience in the biotechnology sector with direct operating experience in the US, Europe and the Middle East
Arix Bioscience launches strategy review
"We believe it is necessary to accelerate the development of our capabilities to ensure we make the most of the opportunities before us," said chairman Naseem Amin
Archive
Proactive news headlines: Arix Bioscience, Powerhouse Energy, EQTEC, Samarkand Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Proactive news headlines: Arix Bioscience, Gfinity, Eco (Atlantic) Oil & Gas, Union Jack Oil…
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience responds to open letter from Acacia Research Corp
The firm said it was “disappointed” that Acacia had decided to publish the letter on the same date as delivering it to the company, adding that it has “an experienced board that is committed to acting in the best interest of all shareholder
Arix Bioscience sees sharp uplift in net asset value in 2020
The highlight of the year was receiving £158mln from the sale of its stake in VelosBio, giving the venture capital firm plenty of firepower for more investments
Arix Bioscience brings in new non-executive directors
Both James Noble and Axel Wieandt will be joining the board effective from April 1
Arix Bioscience says portfolio company Autolus seeks US$100mln IPO
The biopharma is placing 14mln American depositary shares at US$7 each
Arix Bioscience says its managing director to depart for new post
Naseem Amin, Arix’s executive chairman, said Jonathan Tobin leaves with the company's very best wishes
Arix Bioscience portfolio firms Autolus and Imara issue updates
Nasdaq-listed Autolus said it is prioritising its AUTO1 treatment for Adult Acute Lymphoblastic Leukemia, with full data from its AUTO1-AL1 study expected in 2022
Archive
Small Cap Wrap - TruFin, Eagle Eye Solutions Group, Tungsten Corp and more...
HSS Hire Group,HSS.L transfer from Main to Aim. Mkt Cap c. £70m. Recently raised £52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for mo
Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment
The date set by the FDA for a decision is September 30, 2021
Arix Bioscience: Portfolio company Harpoon Therapeutics makes progress on multiple fronts
Harpoon said it had the potential for multiple data releases in 2021 on all four of its programs
Arix BioScience notes Autolus Therapeutics data from lymphoma trial
Dr Christian Itin, chairman and chief executive officer of Autolus, said: “This differentiated profile may widen the potential use of CAR T therapy in DLBCL.
Arix BioScience notes encouraging data from Autolus’ leukaemia treatment trial
AUTO1 is an anti-cancer CAR T-cell therapy currently going through a phase 1 clinical trial
Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn
Arix is the largest shareholder in Artios with a 12.7% stake on a fully diluted basis
Arix Bioscience rockets higher as Merck buys investee company VelosBio for US$2.75bn
The price represents a twelve times return on Arix's original £12mln investment
Arix Bioscience says portfolio company LogicBio Therapeutics announces pricing for public offering
The firm will issue 7mln shares of common stock at US$6 each for total gross proceeds of approximately US$42mln
Arix Biosciences notes new data from Autolus on lymphona treatment
“The data support a best in class profile with a high level of complete remissions and a well-tolerated safety profile”
Arix Bioscience enters final quarter of 2020 with strong momentum
The first half of the year saw the business refocused and streamlined, resulting in sharply reduced operating costs, at the same time, the group's NAV headed north at a rate of knots
Arix Bioscience portfolio company LogicBio announces IND clearance for LB-001
LogicBio said it expects patient enrolment to begin in early 2021.
Arix Bioscience investee company Amplyx announces positive Phase 2 data
Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations
Arix Bioscience says portfolio company Atox Bio plans NDA submission for Reltecimod drug in third quarter of 2020
The plans follow results from a phase 3 clinical trial of Reltecimod which showed positive effects on resolution of organ dysfunction in patients suffering with necrotizing soft tissue infection
Arix Biosciences portfolio company VelosBio completes US$137mln Series B financing
The proceeds will be used to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101
Arix Bioscience portfolio firm Aura Biosciences presents updated data for choroidal melanoma treatment
The firm also announced new data from two other portfolio firms, Imara and Autolus Therapeutics
Arix Bioscience announces Christian Schetter’s move to a managing director role
Schetter's appointment was one of three changes, which also included the establishment of both a scientific advisory board and a board investment committee
Arix Bioscience portfolio companies Autolus and Harpoon present updates at ASCO
Arix has a 6.45% stake in Autolus and 10.4% in Harpoon
Arix Bioscience portfolio company Amplyx Pharmaceuticals raises US$53mln
New investors in Amplyx include Pfizer and Adage Capital
Arix Bioscience's portfolio to be in spotlight at prestigious cancer event, says research house
Given that there is increasingly positive momentum behind life sciences companies in the COVID-19 environment, the current 47% discount to NAV should be viewed as an opportunity"
Arix Bioscience’s Pharmaxis says myelofibrosis treatment well tolerated in clinical trial, advances to Phase 2
Pharmaxis said it will update on Phase 2 once it receives final regulatory clearance in the third quarter of 2020
Arix Biosciences notes investee company Harpoon's US$50mln milestone receipt
The Phase 1/2 clinical trial is targeting relapsed, refractory multiple myeloma
As Gilead news lifts world markets, Arix Bioscience expert takes look at biotech "tools" being deployed in the fight against the illness
The Gilead Sciences Inc (NASDAQ:GILD) report has given a nudge to the FTSE 100, which registered a triple-digit gain; Wall Street is primed to open in positive territory too
Arix Bioscience says portfolio company Autolus to start study on leukaemia lead candidate
Arix said the clinical study will suffer “minimal” impact from the coronavirus outbreak
Arix Bioscience shuffles board, names Naseem Amin as executive chairman with immediate effect
Amin, who joined the Arix board in December 2019, has broad life sciences experience in both the US and Europe, having held senior positions in major healthcare businesses in R&D, business development, marketing, and in venture capital
Arix Bioscience to invest US$3.0mln in IPO by portfolio company, Imara Inc to retain 9.4% stake
Imara has priced its Nasdaq IPO of 4,700,000 shares of common stock at a public offering price of US$16.00 per share for aggregate gross proceeds of $75.2mln
Arix Bioscience focuses on “driving realisable value” after volatile year for markets
The firm exited 2019 in a strong financial position with some £55mln in the bank
Arix appoints entrepreneur in residence to source European investment opportunities
Iacone previously served as director and global head of the Rare Diseases Research division at Swiss pharma giant Roche
Arix Biosciences portfolio company Aura encouraged by trial results of eye cancer treatment
Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020
Arix Bioscience reveals one of its portfolio companies, Imara Inc. has applied to list on Nasdaq
Imara is a clinical-stage biotechnology company focused on developing new medicines to treat patients suffering from rare inherited genetic disorders of haemoglobin
Arix Bioscience investee company Autolus publishes encouraging additional data from blood cancer drug study
The updated data continue to support “early indications of durability and high level of activity previously reported”, Autolus said
Arix Bioscience says company co-founded in 2018 completed Series A financing, bringing total committed funding to $50mln
It teamed up with US venture capital group Atlas Venture to create pre-clinical stage firm Quench Bio, which is working on the first anti-inflammatory and autoimmune drugs targeting a protein called Gasdermin D
Arix Bioscience says portfolio company Autolus Therapeutics prices shares at US$11 each
In total it has put up for sale 7.25mln American Depositary Shares that will bring in a ‘gross’ US$80mln
Arix Bioscience appoints industry heavyweight to board
Amin has 25 years experience and is currently chief executive at GMP-Orphan and venture partner at Advent Life Sciences
Arix Bioscience notes portfolio company Iterum releases topline results for a Phase 3 trial of novel antibiotic, sulopenenem
Iterum said the full body of evidence from the trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 3, confirms overall safety profile
Arix Bioscience hails promising results from Autolus' T-cell cancer therapy trials
Autolus now plans to advance toward a pivotal clinical trial in acute lymphoblastic leukemia, with initiation targeted for the first half of 2020
Roth repeats Buy rating on Arix Bioscience's portfolio company Harpoon Therapeutics
The Buy rating comes after Harpoon granted phama giant Abbvie an exclusive option over the rights to a treatment for a type of blood cancer
Arix Bioscience portfolio company Harpoon agrees US$2.4bn deal with Abbvie
For each of the targets, Harpoon will receive a milestone payment of $310mln each upfront plus royalties on global sales.
Arix Bioscience investee company strengthens pipeline
The venture capital firm applauded the exclusive deal inked by Artios Pharma
Arix Bioscience has “multiple shots on goal”, ShoreCap initiates as a ‘buy’
The stockbroker highlights that with 12 core investments there are multiple chances in the portfolio for success.
Arix Bioscience flags “signs of efficacy” at Aura eye cancer trial
“If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades”
Jefferies puts 229p target on Arix Bioscience
“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said
Arix Bioscience leads €20mln investment round that strengthens position in oncology
New investee company STipe Therapeutics is working on harnessing the immune response to target a range of tumours
Arix Bioscience edges higher after positive news from one of its portfolio companies
Arix is a global venture capital company focused on investing in and building breakthrough biotech companies
Arix jumps as Woodford finally sells stake in Autolus Therapeutics
Autolus shares have been hampered in recent months as investors waited for Woodford to unload his stake in the firm, causing a knock-on effect for Arix
Arix Bioscience and its portfolio companies set for busy year
There are lots of data readouts and new trial starts pencilled in for the next 18 months
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Archive
Proactive news snapshot: Tower Resources, ECSC Group, Motif Bio, Asiamet Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience portfolio company Autolus Therapeutics raises US$109mln
The total of US$109mln is more than Autolus had originally set out to raise from the market
Archive
FTSE 100 ahead at the close as investor appetite returns
The premier UK share index finished around 33 points higher at 7,469
Archive
Proactive news snapshot: Mosman Oil & Gas, Rose Petroleum, Vast Resources, Faron Pharmaceuticals …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Dev Clever slides after receiving go-ahead to deploy its "first live interactive experience"
A look at the day's major movers, including Vast Resources, Cyanconnode, Trackwise, Mosman, UKOG, 7digital, Scapa and easyHotel
Arix Bioscience to invest another US$5mln in Autolus
Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each
Investments and investor services
Vp hit by Competition and Markets Authority decision
A look at the day's major movers, including The Mission Marketing Group, Sirius Minerals, 7digital, Nuformix, Defenx and Shearwater
Archive
Proactive news snapshot: ReNeuron, AFC Energy, Collagen Solutions, AppScatter …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience confirms Autolus to launch proposed public offering
The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering
Investments and investor services
FTSE 100 closes in the red as Brexit and trade war fears continue to hit sentiments
The International Monetary Fund issued a warning, saying a "no-deal" Brexit would send the British economy into severe shock
Archive
Proactive news snapshot: Tekcapital, Mirada, European Metals Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Superdry investors in danger of losing their shirt after Dunkerton prevails in power struggle
A look at the day's major movers, including Clear Leisure, Proteome, Intercede, MP Evans, Zenith Energy, Infrastructure India and Sabien Technology
Arix Bioscience increases stake in cutting-edge cancer company after backing its latest financing round
The venture capital company committed £3.4mln to Aura Biosciences' Series D financing round
Autolus Therapeutics presents promising leukemia trial data at American Association for Cancer Research's annual meeting
After one month, eight of the nine patients who could be evaluated in the study reported a molecular complete response or no evidence of cancer via CT or PET imaging
Archive
Aukett Swanke subsides after downbeat AGM statement
A look at the day's major movers, including Ironveld, Brave Bison, Pebble Beach, Zanaga, Debenhams, 7digital and Diurnal
Archive
Proactive news snapshot: Europa Metals, Ceres Power, Arix Bioscience, Hurricane Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Arix Bioscience upbeat on prospects after making "encouraging progress" last year
The net asset value, which is closely monitored by the market, was £270mln, or £2 a share, a rise of 48p from a year ago. The stock closed Wednesday at 144p
Archive
Blue chips to swerve Thursday’s Brexit fall-out, small caps will be in spotlight
IGas and Gulf Keystone are on the agenda, meanwhile Brexit will likely be a talking point for Eddie Stobart Logistics.
Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day
Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses
Archive
Proactive news snapshot: ValiRx, Erris Resources, Personal Group, S&U …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Fizzy drinks on the table as Fevertree Drinks and AG Barr both provide updates
Aside from the fizzy drinks firms, the Day Ahead will also bring updates from plumbing and heating products supplier Ferguson and North West Water firm United Utilities
Archive
Brexit date arrives but March 29 to be a damp squib although parliamentary vote might not be
Aside from the latest instalment of the Brexit saga, the week ahead will bring updates from housebuilder Bellway, tobacco firm Imperial Brands, and soft drinks group Fevertree
Archive
Proactive news snapshot: WideCells Group, Tlou Energy, Oriole Resources, Strategic Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Defenx on the back foot as it draws down last of its loan facility
A look at the day's major movers, including AssetCo, Restore, Miton, Maintel, Microsaic, Footasylum, TomCo, GoldStone and Bluebird
Arix Bioscience invests US$15mln in sickle cell treatment developer Imara
The health and life science investor said the sum would give it a 10% stake in the company and expand the breadth of its portfolio
Investments and investor services
FTSE 100 closes higher as Bercow deals blow to May's Brexit plan
Bercow says the government can only bring back the vote if there has been substantial 'change' to the Brexit deal
Archive
Proactive news snapshot: Seeing Machines, Arc Minerals, Strategic Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience appoints Joe Anderson CEO in boardroom reshuffle
Executive chairman Jonathan Peacock will stay in role, but in a non-executive capacity
Investments and investor services
FTSE 100 closes in red as lack of positive news puts traders off
The UK's blue chip benchmark closed down around 40 points at 7,179, while FTSE 250 shed around 58 at 19,068
Investments and investor services
Edenville Energy plunges after Tanzanian setback
A look at the day's major movers, including Sabien technology, Stock Spirits, Simigon,UK Oil & Gas, Tungsten, WANdisco, Restaurant Group and Titon
Archive
Proactive news snapshot: Strategic Minerals, Feedback, Redx Pharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Hardware & electrical equipment
Arix Bioscience quids in after Harpoon completes flotation on NASDAQ
Harpoon is well-positioned to play a significant role in immuno-oncology, Arix said
Archive
FTSE 100 closes a tad higher but sentiment dented by US data
FTSE 100 closed up just over six points at 7,197, while FTSE 250 shed over 74 at 18,898
Archive
Proactive news snapshot: Tower Resources, Katoro Gold, Arix Bioscience …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Integumen surges as it announces roll-out of partnership management platform
A look at the day's major movers, including Pressure Technologies, 7digital, Hardide, GLI Finance, Modern Water and Mporium